Neuralink Hits 20 Active Patients as It Races Toward 1,000 Implants

FREMONT, Calif. — Neuralink has implanted its brain-computer interface device in 20 people, roughly doubling the patient count from 12 reported in late 2025, as the company enters a high-volume production phase supported by a fully automated surgical robot. The milestone marks a pivotal transition for a company that spent its first years proving the technology works and is now building the infrastructure to implant thousands.

From 12 to 20 and Climbing

The jump from 12 to 20 active trial participants in a matter of months reflects an acceleration in Neuralink's clinical enrollment pace. All current patients are individuals with severe paralysis — spinal cord injuries, ALS, or comparable neurological conditions — who are using the implant to control digital and physical devices with their thoughts.

Participants have demonstrated the ability to operate computer cursors, navigate the internet, control robotic arms, and interact with social media applications using neural signals alone. One patient posted publicly on X using only their thoughts, providing one of the most vivid demonstrations of the technology to date.

The company's target for 2026 is reaching 1,000 implanted patients — a roughly 50-fold expansion from where Neuralink was entering the year.

The R1 Surgical Robot Changes the Equation

Neuralink's path to 1,000 implants runs through the R1 — its nearly fully automated surgical robot. The R1 can guide electrode wires through the dura mater, the brain's outer protective tissue layer, without removing it. That approach reduces surgical complexity and patient recovery time compared to earlier methods that required manual membrane manipulation.

The entire procedure now completes in under 30 minutes. The robot uses high-precision cameras and sensors to navigate around blood vessels on the brain's surface with zero-bleeding accuracy. At an electrode insertion speed of 1.5 seconds per channel, the R1 can complete what once required hours of neurosurgical manual work in a single automated session.

Automation is essential to reaching scale. With a human surgical team, implant procedures are limited by scheduling, surgeon availability, and operating room access. A robotic system operating at clinical-grade precision removes those constraints and makes triple-digit monthly implant volumes feasible.

$650 Million in Funding Fuels the Ramp

The production expansion is supported by $650 million raised in a Series E funding round, bringing Neuralink's total funding to approximately $1.3 billion since its 2016 founding. Investors including ARK Invest, Sequoia Capital, Founders Fund, and Thrive Capital participated, valuing the company at $9 billion pre-money.

The capital is being deployed across three fronts: scaling device manufacturing, expanding the automated surgical program, and advancing the Blindsight chip — a separate device targeting patients who have lost their sight. Blindsight recently entered its first human trials, representing a meaningful expansion of Neuralink's addressable patient population beyond motor impairment into sensory restoration.

What the Roadmap Looks Like

Neuralink's near-term focus remains on patients with the most acute medical need — those for whom the technology represents a life-altering restoration of autonomy. Reaching 1,000 implanted patients in 2026 would represent a proof point that the R1 robot and automated pipeline can operate at meaningful clinical scale, not just in a handful of highly curated cases.

For the broader trajectory of brain-computer interface technology, the numbers matter enormously. Every patient enrolled generates longitudinal data on device performance, signal stability, and long-term safety that feeds directly into next-generation designs and future regulatory submissions.

With 20 active patients, a production-ready surgical robot, and one of the deepest funding bases in neurotech, Neuralink is entering the phase where the technology begins to define what is actually possible — not just what has been demonstrated.